Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.55 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.33 |
| ▸ | ABL1 | P00519 | 4/20 | 0.33 |
| ▸ | EGFR | P00533 | 4/20 | 0.33 |
| ▸ | HCK | P08631 | 4/20 | 0.33 |
| ▸ | SRC | P12931 | 4/20 | 0.33 |
| ▸ | KDR | P35968 | 4/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.33 |
| ▸ | MTOR | P42345 | 4/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.33 |
| ▸ | PRKDC | P78527 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1816456 | 1.00 | AR (0.55) | AREGLN2GRM2PIK3CDPIK3CG | |
| SCHEMBL1813045 | 1.00 | AR (0.55) | AREGLN2GRM2PIK3CDPIK3CG | |
| SCHEMBL1813787 | 0.93 | AR (0.49) | AREGLN2GRM2PIK3CDPIK3CG | |
| SCHEMBL13734792 | 0.93 | AR (0.49) | AREGLN2GRM2PIK3CDPIK3CG | |
| SCHEMBL1813786 | 0.93 | AR (0.49) | AREGLN2GRM2PIK3CDPIK3CG | |
| SCHEMBL1815432 | 0.77 | AR (0.52) | AREGLN2 | |
| SCHEMBL1815435 | 0.77 | AR (0.52) | AREGLN2 | |
| SCHEMBL1818302 | 0.77 | AR (0.52) | AREGLN2 | |
| SCHEMBL15729287 | 0.76 | KMT2A (0.46) | AREGLN2PIK3CDPIK3CGPIK3CA | |
| SCHEMBL1814475 | 0.76 | AR (0.44) | AREGLN2TRPV4NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| EP-3885340-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2021-09-29 | — | — | EP | disclosed |
| US-11046713-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2021-06-29 | — | — | US | disclosed |
| EP-3369732-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2021-05-26 | — | — | EP | disclosed |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2020-09-24 | — | — | US | disclosed |
| US-10711013-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2020-07-14 | — | — | US | disclosed |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2019-04-04 | — | — | US | disclosed |
| US-10118933-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2018-11-06 | — | — | US | disclosed |
| EP-3369732-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2018-09-05 | — | — | EP | disclosed |
| EP-3056485-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2018-05-09 | — | — | EP | disclosed |
| US-9657003-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2017-05-23 | — | — | US | disclosed |
| EP-3056485-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2016-08-17 | — | — | EP | disclosed |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION | 2015-07-23 | — | — | US | disclosed |
| US-8975254-B2 | Androgen receptor modulating compounds | ORION CORPORATION (FI) | 2015-03-10 | — | — | US | disclosed |
| EP-2493858-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2014-07-02 | — | — | EP | disclosed |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-09-06 | — | — | US | disclosed |
| EP-2493858-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | Orion Corporation (FI) | 2012-09-05 | — | — | EP | disclosed |
| CN-102596910-A | Androgen receptor modulating compounds | ORION CORP | 2012-07-18 | — | — | CN | disclosed |
| WO-2011051540-A9 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011051540-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORPORATION (FI) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10118933-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | AR 1/4885EGLN2 2169/4885GRM2 403/4885 |
| US-10711013-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | AR 1/4885EGLN2 2169/4885GRM2 403/4885 |
| US-20200299307-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | AR 1/4885EGLN2 2169/4885GRM2 403/4885 |
| US-20190100536-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | AR 1/4885EGLN2 2169/4885GRM2 403/4885 |
| US-11046713-B2 | Androgen receptor modulating compounds | AR, NR5A1, SHBG | AR 1/4885EGLN2 2169/4885GRM2 403/4885 |
| US-20150203479-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | AR 1/4885EGLN2 2169/4885GRM2 403/4885 |
| US-20120225867-A1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | AR, NR5A1, SHBG | AR 1/4885EGLN2 2169/4885GRM2 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.